The cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4)/B7 and programmed death 1
(PD-1)/programmed cell death-ligand 1 (PD-L1) are two most representative immune …

Programmed death-ligand 1 (PD-L1) is an immune checkpoint inhibitor that binds to its
receptor PD-1 expressed by T cells and other immune cells to regulate immune responses; …

Although the role of PD-L1 in suppressing the anti-tumor immune response is extensively
documented, recent discoveries indicate a distinct tumor-intrinsic role for PD-L1 in …

Immune checkpoint blockade therapies (ICBTs) targeting programmed cell death 1 (PD-1)
and its ligand programmed death ligand-1 (PD-L1/B7-H1/CD274) have exhibited …

Breast cancer is the most frequently occurring cancer in women. Chemotherapy in
combination with immunotherapy has been used to treat breast cancer. Atezolizumab …

A growing amount of evidence suggests that ubiquitination and deubiquitination of
programmed death 1 (PD-1)/programmed death-ligand 1 (PD-L1) play crucial roles in the …

Incomplete understanding of the metastatic process hinders personalized therapy. Here we
report the most comprehensive whole-genome study of colorectal metastases vs. matched …

With the recent approvals for the application of monoclonal antibodies that target the well-
characterized immune checkpoints, immune therapy shows great potential against both …

The immune checkpoint molecules programmed cell death receptor 1 (PD-1) and
programmed death ligand 1 (PD-L1) are one of the most promising targets for tumor …

Abstract PD-L1 (CD274) is a well-known immunosuppressive molecule, which confers
immunoescape features to cancer cells and has become one of the major targets in cancer …